SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
latest_posts
- 1
Brazil's former President Jair Bolsonaro seeks house arrest for prison time citing health issues - 2Flu activity in US could continue to rise for weeks, top CDC epidemiologist says
- 3Overlooked infertility care should be part of national health services, says WHO
- 4This Tiny Neon Frog Dwells in the Clouds
- 5Vote in favor of the wide open action that revives your brain and soul!
- Russian strikes on Ukraine kill 5 people and wound 30 more
- 5 High Limit Outer Hard Drives For Information Stockpiling
- Hostile to Maturing Skincare Items to Rejuvenate Your Skin
- How much would you pay to meet a Real Housewife? At BravoCon, the limit does not exist.
- Finding the Universe of Craftsmanship: Individual Encounters in Imagination
- Analysis-NASA's moon mission tests aerospace old guard as SpaceX, Blue Origin hover
- What to know about new CDC deputy director who has been critical of COVID vaccines
- 4 Creative Savvy Home Gadgets of 2024: Reforming Home Robotization and Security
- Anger as German family business group opens talks with far-right AfD
